Lead Sponsor

Eli Lilly and Company

Collaborators

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Must be female and greater than or equal to 18 yrs of age
•Participants must have confirmed cancer with measurable or evaluable, locally recurrent or metastatic disease.
•Participants must have received a taxane as neo-adjuvant and/or adjuvant therapy
•Participants may have received prior hormone therapy for locally recurrent or metastatic disease

•Participants with breast cancer overexpressing Human Epidermal growth factor Receptor 2 (HER2) gene amplification
•Prior chemotherapy or targeted therapy for metastatic breast cancer
•Prior treatment with gemcitabine, trastuzumab, lapatinib or bevacizumab in any setting
•History of, or active brain mets
•Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to treatment, or anticipation of need for major surgical procedure during course of study
•Prior history of high blood pressure crisis
•Have a serious, nonhealing wound, ulcer, or bone fracture

Related studies

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer

NCT06428396 · Metastatic Breast Cancer

NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer

NCT05534438 · Oligometastatic Breast Carcinoma, Breast Cancer, and more

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer